semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain The sample will consist of 15 pregnant participants (ideally between the 2nd and 3rd trimester of gestation) with chronic idiopathic low back pain and a group of 15 non-pregnant women with chronic idiopathic low back pain  Pregnant women with risk pregnancy will be excluded as well as low back pain with a known cause (e.g. radiculopathy) and all participants with serious pathologies (e.g. history of trauma, surgery for less than 12 months, neurological pathologies, tumors)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Graves Ophthalmopathy Graves Disease Autoimmune Thyroiditis for Graves' disease: a history of hyperthyroidism, associated with previous or present detectable serum autoantibodies against the TSH-R; 2. for autoimmune thyroiditis: the presence of at least two of the following: a) primary hypothyroidism; b) detectable serum autoantibodies against thyroglobulin or thyroperoxidase ; c) a hypoechoic pattern of the thyroid by ultrasound examination. 3. for healthy subjects: absence of any clinical, biochemical or instrumental evidence of thyroid diseases. For all subjects: Informed consent  lack of informed consent
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Von Willebrand Disease Historically lowest VWF:Ag and/or VWF:RCo and/or VWF:CB ≤ 0.30 IU/mL and/or FVIII:C ≤ 0.40 IU/mL Treatment at a Hemophilia treatment center in the Netherlands All types of VWD All ages  Other known bleeding disorders present
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Metastatic Malignant Solid Neoplasm Patients with biopsy-proven metastatic solid tumor and be eligible to receive nivolumab per standard of care Patients will be allowed to have any number of prior lines of therapy for metastatic cancer Patients with measurable and non-measurable disease are allowed to participate Absolute neutrophil count (ANC) ? 1.5 x 10^3/mm^3 Hemoglobin (Hgb) ? 9 g/dL Platelet count ? 100 x10^3/mm^3 Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN) or ? 5 x ULN in patients with liver metastases Prothrombin time ? 1.5 x ULN Total bilirubin ? 1.5 x ULN (unconjugated bilirubin of < 3 x ULN for patients with known Gilbert syndrome) Creatinine clearance of ? 50 ml/min by Cockcroft-Gault equation  History of prior therapy with ibrutinib or nivolumab Unable to swallow capsules or having disease that is significantly affecting gastrointestinal function and/or inhibiting small intestine absorption Diagnosis of congenital or acquired immunodeficiency with the exception of chemotherapy induced immune suppression Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids of greater than or equal to prednisone 10 mg/day or other immunosuppressive agents; patients with history of adequately treated Hashimoto?s thyroiditis will be eligible; patients requiring a short course of a high dose prednisone burst to treat asthma or common obstructive pulmonary disease will also be eligible 5 days following completion of the prednisone treatment Use of systemic steroids at a dose above 10 mg/day of prednisone or prednisone equivalent in cycle 1 of study therapy; systemic steroids must be discontinued at least 5 days prior to initiating study therapy; exception will be given to patients who develop immune related adverse events that necessitate use of steroids or other immune suppressive agents; following cycle 1 of study treatment, the use of systemic steroids will be allowed per discretion of the treating physician Active, non-infectious pneumonitis Ongoing or active infection requiring systemic therapy History of being positive for human immunodeficiency virus (HIV) History of hepatitis B or C History of receiving live vaccine within 30 days of planned start of study therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Obesity Age 20-60 years BMI 25-35 kg/m2 Abdominal obesity (Waist circumference): Male >90 cm, Female >85cm  Cardiovascular events within 3 months uncontrolled hypertension (>160/100 mmHg) Diabetes mellitus Dyslipidemia under statin therapy TSH<0.1 uU/ml or>10 uU/ml Elevated creatinine level (twice higher than upper normal limit) Elevated AST/ALT level (three times higher than upper normal limit) Pregnancy, lactation
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Rare Diseases Orphan Diseases first contact with the Center for Rare Diseases for unclear diagnosis suspicion of a rare disease but no established diagnosis attending the Center for Rare Diseases as an outpatient written informed consent  age <12 years incomplete medical records including summary letters, imaging studies, blood tests etc pre-diagnosed disease(s) explaining all symptoms
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-45.0,  Anemia, Iron Deficiency Age 15-45 years old at intake Confirmed intrauterine pregnancy by 1st trimester ultrasound  Antepartum iron supplementation, other than prenatal vitamins Placental abruption or hemorrhage Initial visit >20 weeks gestation Diagnosis of sickle cell disease or thalassemia Diagnosed with anemia at initial prenatal visit Diagnosis of autoimmune issues that could effect iron levels
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Microbiota Age 18 years old, 65 years old, male and female Histologically confirmed differentiated thyroid cancer After total thyroidectomy, patients who have undergone 131I therapy for the second time or more after recurrence or regional lymph node metastasis after 131I treatment for the first time are required. Or after the first 131I treatment, patients with differentiated thyroid who were treated with 131I for more than 3 months  Use of various antibiotics within three months Having a history of alcoholism for more than 2 years and a history of smoking throughout the year pregnancy or lactation having oral, respiratory and gastrointestinal diseases has a variety of metabolic diseases, such as obesity, hypertension, diabetes, stones, various liver diseases, etc having other autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, etc History of gastrointestinal surgery or other recent surgical history Has a family history of genetic disease, mental illness, etc Research subjects are participating in other research topics The researchers believe that other reasons are not suitable for continuing clinical trials
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Pediculoses Includes lists of body weight ≥ 15 kg for oral administration to ivermectin, • Obtain the signed informed consent of the parent or caregiver for his participation in the study. Includes lists of Refusal of participation Non-residents in the villages during the study period body weight <15 kg not eligible for oral administration with ivermectin Pregnant women, who in the context of the daily medical and epidemiological monitoring of the population of Dielmo-like that of Ndiop are identified and very early at the looking at the first signs of conception in a pregnant woman from her state of pregnancy on the basis of a proven test. In addition, before any treatment with ivermectin, will be systematically requested from each of the target women of reproductive age if she is pregnant Women breastfeeding at the time of the study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-45.0,  Acne Vulgaris Thyroid Dysfunction Patient with acne vulgaris from females only with different ages (starting from 16 years) , BMI groups  Female patients with clinically diagnosed thyroid disease Female patients receiving isotretinoin or minocycline in the last 6 months Female patients who were subject to radiotherapy or surgery in neck region
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.442-0.615,  Weight Gain Gestational age in weeks: 23 weeks 0 days and 31 weeks 6 days Birth weight less or equal to 1500 g Minimum enteral intake of 150-160 mL/kg/d fortified HM Parents, liable parent, or legal representative (LR) if applicable are willing and able to sign written informed consent and written informed consent is obtained prior to trial entry  Infants with weight z-score < -2 SD, based on the Fenton growth chart (Fenton 2013) Intra-ventricular hemorrhage (grade 3-4) determined using cranial ultrasonography or periventricular leukomalacia Renal disease determined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased creatinine Cholestasis (total bilirubin > 5 mg/dL or 85 umol/L and direct bilirubin > 20% of total bilirubin) associated with one or more abnormal liver function tests (AST, ALT, or GGT) Major congenital malformations that may impact ability to accept enteral feedings (i.e., severe cleft palate, etc.) Suspected or documented systemic or congenital infections (i.e., human immunodeficiency virus, cytomegalovirus, etc.) Evidence of cardiac, respiratory, endocrinologic, hematologic, gastrointestinal, or other systemic diseases that may impact growth, e.g NEC grade above or equal to 2 Uncontrolled sepsis Suspected or documented maternal substance abuse
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Weight Gain Very preterm infant ( <32 weeks at birth) On full enteral feeds for more than 2 weeks (full feed is defined at the time of reaching 120 ml/kg/day with no parenteral nutrition used) Poor weight gain (<15 g/kg per day) despite optimization of energy and protein intakes by RDs (calories intake: 125-135 Kcal/kg per day and protein: 4-4.5 g/kg per day) Mothers have enough milk supply (>150% of infant's daily needs)  Congenital anomalies Small for gestational age infants (< 10th percentile) at birth
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Cystic Fibrosis-related Diabetes Age >/= 6 years 2. Diagnosis of cystic fibrosis 3. CF patients regularly attending the CF centers 4. Clinically stable in previous 3wks absence of major clinical events including pulmonary exacerbations no change in their habitual treatment regimen including introduction of antibiotics or steroids in the past 3 weeks  Diagnosis of type 1 diabetes, type 2 diabetes, or MODY 2. Organ transplantation 3. new diagnosis of CFRD in the past 6 months 4. antidiabetic treatment in past 6 mos (insulin or oral hypoglycemic agents) -patients with previous CFRD diagnosis, but not currently taking insulin/glucose-lowering medications for at least 6 months should be included 5. pulmonary exacerbation associated with systemic steroid requirement in the last 6 months 6. on CFTR corrector less than 6 months prior to enrollment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.167-0.5,  Severe Acute Malnutrition Group 1 (SAM) Infants between 2 and <6 months old with SAM as defined by weight-for-length < -3 Z and/ or bilateral pedal edema either sex caregiver willing to provide consent for enrolment of the infant caregiver willing to stay in the Nutritional Rehabilitation Unit for about 15 days residence within 15 km from icddr,b Group 2 (non-malnourished) Non-malnourished infants (WLZ ≥ -1) <6 months old who are hospitalized for treatment with antibiotics for infection (infants who come with a history of antibiotic intake for 3 days or more will be eligible; the last dose of such an antibiotic will have to be taken within last 24hours, the antibiotic intake should be documented by the verification of a prescription, the bottle of antibiotic or asking the caregiver about the name of antibiotic or its price and how it is reconstituted) infant receiving at least 50% of nutritional intake from breast milk at the time of hospitalization either sex residence within 15 km from icddr,b  Septic shock or very severe pneumonia requiring assisted ventilation acute kidney injury on admission congenital defects interfering with feeding such as cleft palate chromosomal anomalies jaundice tuberculosis presence of bilateral pedal edema ongoing maternal antibiotic usage for breastfeeding infants Group 1 (SAM) additional Infants receiving ≥75% of nutrition from breast milk Group 2 (non-malnourished) additional Infants receiving <50% of nutrition from breast milk
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-30.0,  Pregnancy and Early Lactation Among Women Living in an Area Endemic for Malnutrition all women who become pregnant during a 9-month period in a set of Nagarpalikas and Gaunpalikas in Sarlahi District, Nepal  Women who do not intend to deliver their child in the study area Women who are allergic to milk, nuts or soy Women who are unwilling to commit to daily consumption of the nutritional supplement if they are randomized to an active treatment arm Women who refuse to provide consent
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 8.0-16.0,  Cerebral Palsy Children diagnosed spastic cerebral palsy Children wearing night splint ankle foot orthoses all night long during 1 week minimum Children with a level of spasticity in the gastrocnemius muscle greater than or equal to X1, VII, on the Tardieu scale and 2 on the Ashworth scale Children able to understand and respect the simple instructions of the study Children and parents who received informed information about the study and who co-signed, with the investigator, a consent to participate in the study  Children who do not tolerate ankle foot orthoses all night long Children who had botulinum injection in gastrocnemius or soleus muscles during last three months Children benefiting from an injection of botulinum toxin or the setting up of new equipment during the protocol Children who do not tolerate ankle foot orthoses all night long Children having benefited from plaster lengthening for less than three months
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Head and Neck Cancer Non-thyroid head and neck cancer patients who were treated with RT alone or in combination with surgery and/or chemotherapy  Patients with thyroid gland disease or abnormal thyroid hormone levels before radiotherapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-16.0,  Malnutrition Adolescent Development Adolescent Behavior Is a female participant of girls' club in the school that was randomly selected to participate in the study Resides in the Upper Manya Krobo district Is 12 to 16 years of age  Does not speak local dialect Krobo